[{"orgOrder":0,"company":"Liomont","sponsor":"Liomont","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"||Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Liomont","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Liomont \/ Liomont","highestDevelopmentStatusID":"11","companyTruncated":"Liomont \/ Liomont"},{"orgOrder":0,"company":"Liomont","sponsor":"Infinite Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MEXICO","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etoricoxib","moa":"||Cyclooxygenase-2","graph1":"Neurology","graph2":"Phase II","graph3":"Liomont","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Liomont \/ Infinite Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Liomont \/ Infinite Clinical Research"}]

Find Clinical Drug Pipeline Developments & Deals by Liomont

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 16, 2023

                          Lead Product(s) : Etoricoxib,Tramadol Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Infinite Clinical Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          May 28, 2020

                          Lead Product(s) : Nitazoxanide,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Recipient : Materno-Perinatal Hospital of the State of Mexico

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : EPIC Research CRO | ILS Clinical Research | Q Square Solutions

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 09, 2018

                          Lead Product(s) : Quadrivalent Recombinant Hemagglutinin Influenza Vaccine,Inapplicable

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : EPIC Research CRO | ILS Clinical Research | Q Square Solutions

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank